Key result
A new cardiovascular damage staging classification was independently associated with an increased risk of all-cause mortality (HR 1.49 per 1 stage increase; 95% CI 1.27-1.75; P<0.001).
Why the study?
Current recommendations based on aortic regurgitation severity, symptoms, and left ventricular repercussions provide only modest risk stratification value in patients with chronic aortic regurgitation.
Does a new echocardiography-based cardiovascular damage staging classification predict mortality and cardiovascular hospitalization in patients with chronic significant aortic regurgitation?
Cohort (n=619)
Does a new echocardiography-based cardiovascular damage staging classification predict mortality and cardiovascular hospitalization in patients with chronic significant aortic regurgitation?
Hazard Ratio: 1.49 (95% CI 1.27–1.75)
p-value: p=< 0.001
A novel echocardiography-based cardiovascular damage staging classification provides significant prognostic value for mortality and cardiovascular hospitalization in patients with chronic moderate or severe aortic regurgitation.
May support risk stratification in aortic regurgitation; extends prior staging systems but remains hypothesis-generating.
BACKGROUND: Current recommendations for management of chronic aortic regurgitation (AR) are based on AR severity, symptoms and repercussions on the left ventricle (LV), only providing modest risk stratification value in patients with AR. The objective was to assess the prognostic value of a new staging classification characterizing the extent of cardiovascular damage for risk stratification in patients with chronic AR. METHODS: According to cardiovascular damages at echocardiography, 619 patients with ≥ moderate AR were classified as follows: Stage 0: no cardiovascular damage; Stage 1: LV damage; Stage 2: ascending aorta, left atrial, or mitral valve damage; Stage 3: pulmonary vasculature or tricuspid valve damage; and Stage 4: right ventricular damage. Study primary endpoint was all-cause mortality and the secondary endpoint was a composite of all-cause mortality and cardiovascular hospitalization. RESULTS: Among 619 patients, 85 (13.7%) were in Stage 0, 138 (22.3%) in Stage 1, 278 (44.9%) in Stage 2, 35 (5.7%) in Stage 3, and 83 (13.4%) in Stage 4. After adjustments, cardiovascular damage stage was independently associated with increased risk of all-cause mortality (hazard ratio [HR]; 95% confidence interval [CI] per 1 stage increase, 1.49 [1.27 to 1.75]; P < 0.001) and the composite of events (HR,1.17 [1.03-1.34]; P = 0.02). Stage ≥ 2 was independently associated with increased risk of all-cause mortality (HR, 3.02 [1.83-4.99]; P < 0.001) and the composite of events (HR, 1.88 [1.29-2.73]; P < 0.001). Net reclassification index analyses showed incremental value of the new classification (net reclassification index [NRI] = 0.40; P < 0.001). CONCLUSIONS: This new cardiovascular damage staging classification provides powerful prognostic value in patients with chronic AR and may be useful to enhance risk stratification and trigger intervention, particularly in asymptomatic AR.
No takes yet. Share an insight, caveat, or question.
López-Santi et al. (2025) conducted a cohort in Chronic significant aortic regurgitation (n=619). Cardiovascular damage staging classification vs. Lower cardiovascular damage stages was evaluated on All-cause mortality (HR 1.49, 95% CI 1.27 to 1.75, p=< 0.001). A new cardiovascular damage staging classification was independently associated with an increased risk of all-cause mortality (HR 1.49 per 1 stage increase; 95% CI 1.27-1.75; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: